Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
This approval represents a meaningful shift in obesity treatment
The Great (Oral) GLP-1 Scare Why the Stevanato narrative is flawed This is not something that should take you by surprise because Ive talked about it in the past, but Stevanatos stock has been weak lately (maybe an understatement): This has happened despite the company (imho) receiving incrementally positive news over the past few months
showed that ACTL6A was frequently amplified and highly expressed with TP63 and that they coordinated a regulatory on WWC1 to mediate oncogenic YAP activity, contributing to outcomes of patients with head and neck squamous cell carcinoma 11
In people with both type 2 diabetes and cardiovascular disease, the risk of death from a cardiovascular problem is lowered by: empagliflozin (one of the active drugs in Synjardy) canagliflozin (one of the active drugs in Invokamet) In certain people with type 2 diabetes and kidney damage caused by diabetes, canagliflozin also helps lower the risk of: death from a cardiovascular problem end-stage kidney disease doubled blood level of creatinine (a type of protein) hospitalization from heart failure Drug forms and administration Synjardy and Invokamet both come as tablets that are taken by mouth with food
